scholarly journals Cost-Effectiveness Analysis of Exenatide Twice Daily (BID) Versus Insulin Glargine Once Daily (QD) as Add-on Therapy in Chinese Patients with Type 2 Diabetes Mellitus Inadequately Controlled by Oral Therapies

2015 ◽  
Vol 18 (7) ◽  
pp. A609
Author(s):  
J Deng ◽  
S Gu ◽  
H Shao ◽  
H Dong ◽  
Y Zhao ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Cost Effectiveness ◽  
Insulin Glargine ◽  
Cost Effectiveness Analysis ◽  
Chinese Patients ◽  
Once Daily ◽  
Effectiveness Analysis

scholarly journals Cost-Effectiveness Analysis of Exenatide versus GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus

2019 ◽  
Vol 4 (2) ◽  
pp. 277-286 ◽  
Author(s):  
Margarita Capel ◽  
Andreea Ciudin ◽  
María Mareque ◽  
Raquel María Rodríguez-Rincón ◽  
Susana Simón ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Cost Effectiveness ◽  
Cost Effectiveness Analysis ◽  
Receptor Agonists ◽  
Effectiveness Analysis

Intensive versus conventional treatment on patients with type-2 diabetes mellitus. A cost/effectiveness analysis

2015 ◽  
Vol 241 (1) ◽  
pp. e215
Author(s):  
M. Hernandez-Sanchez ◽  
C. Fernandez-Fernandez ◽  
A. Rodriguez-Guerrero ◽  
L. Martín-Fernandez ◽  
D. Barrio-Carreras ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Cost Effectiveness ◽  
Conventional Treatment ◽  
Cost Effectiveness Analysis ◽  
Effectiveness Analysis

scholarly journals Pharmacoeconomic aspects of the use of sulfonylurea drugs in type 2 diabetes mellitus

2011 ◽  
Vol 14 (3) ◽  
pp. 111-112
Author(s):  
Alla Vsevolodovna Rudakova
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Cost Effectiveness ◽  
Cost Effectiveness Analysis ◽  
Modified Release ◽  
2Nd Generation ◽  
Effectiveness Analysis ◽  
Sulfonylurea Drugs

In Russia, sulfonylurea drugs are extensively prescribed to patients with type 2 diabetes mellitus. This work was designed to study pharmacoeconomicaspects of application of 2nd generation sulfonylureas based on the results of the GUIDE study comparing effects of therapy with gliclazide modifiedrelease (diabeton MV) and glimepiride (amaryl). The two drugs are known to be equally effective, but gliclazide creates a much smaller risk ofhypoglycemia than glymepiride. Cost-effectiveness analysis showed that the use of gliclazide cuts the costs of therapy by 40%. It is concluded that thechoice of gliclazide modified release is economically more feasible than glimepiride.

Sign in / Sign up

Export Citation Format

Share Document